{"name":"Cellenkos, Inc.","slug":"cellenkos-inc","ticker":"","exchange":"","domain":"","description":"Cellenkos, Inc. is a clinical-stage biotechnology company focused on developing cell-based therapies for various diseases. The company's pipeline includes four drug candidates, all currently in Phase 1 trials, targeting areas such as immunology and oncology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNS0w4N0NqcEo4eVliUHR2Z0d4Y0ZCSi12NzJwMjM5WXpUSmg0UGZjbkh0QmJjRG94c2p4UlY2c05ZLW5lb2FoTjBENnNlT3g2alpiZEJXUGs2eHZSR2NuSlVZZGRvWHN0amNGNWRzTU54RE9tSDZHTk1nNFc4U1E0QThMN013UHhYa3pRUjFVd29GR3c?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Competitive Landscape: Key Market Leaders and Emerging Participants in the Aplastic Anemia Market - openPR.com","headline":"Competitive Landscape: Key Market Leaders and Emerging Participants in the Aplastic Anemia Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQZWtIODd4SjhzYU50bUVYazAyOGJCd0VRV3JmSUswZGIyY3pLN2x5UjRLbjhfUTVFLVZIVG9xbmMxU0NJdERhMG5YYnduV0tLb2tzUlRRYkVxcFlLRDE0am1GSzkyZGtDbTBVYWdJalpqUy1oY3VCcnAwcGhnZUFESmdRXy0tUWtCNWFCbGhVZU1TSWRBdEZpOU5GaXNTS1E2bFgtQ2RZdEk4SGpac3FERGVORzExQzFjdGxuQkZIMGZSTWpxaXFhQmw2TnN6ZHFFS3BBZzdHLW9BR1lkMldrcmRDeVJFT3JZTWc?oc=5","date":"2026-01-06","type":"regulatory","source":"PR Newswire","summary":"FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of Myelofibrosis - PR Newswire","headline":"FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of Myelofibrosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQNnpDMkd0NkV5SHVxVnNiSGo3bWtqd1pDQkY3N0FhaFZfdmNUS2VDeld6bkRZR1lqN1VadlZ1ajc2M0d6ejRvMG1DTkVXR2t5OU9lMmc4c0p1a1dxY0htWldlOXQ5RWJmb2VqTUtoTWlPeXFlR2wwQTZyRzZUWURiRVdqUF8yM2JRbWdGLUlwSmFyTkJyTTZlbTlfc3I5VGR0clZCa1V5aVkwa0lpZmFHTVZ3RzBHUGR5QkgxQTN2ZWpwNkJmZmdIUngyWnNYQjluSGJJZVRkaHFJNW9hX004WXFkUkdQcUtvbE5pZERBMGxJWHRBTGc?oc=5","date":"2025-10-20","type":"regulatory","source":"PR Newswire","summary":"FDA Grants Orphan Drug Designation to Cellenkos' CK0803 Tregs for Treatment of Amyotrophic Lateral Sclerosis - PR Newswire","headline":"FDA Grants Orphan Drug Designation to Cellenkos' CK0803 Tregs for Treatment of Amyotrophic Lateral Sclerosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxNQXg1OTBYS1ZMSDhzVU1nTlpNaURuUXhFMUEzZHoyWE5FQ3VDdk9MTHhPTWFSWTZjckNuYUVRaW4wUjJodEVaSm9fLTNPUUM2cVdhTFlmZWRHTVdiRThhR3I1c3ZDN0dPSVVDN1Q4YzJ0UXowbk44SHRYTTZqQ3U1UTNpMVhkYThUY1RWZTRRTUlraG16TU5JM3gybDZJdXgzcWJIamZ0VERHdld0akVhVm0xMFM2N1FuS1hTS29zZDR5WG9GZWp2TFNqcXdjbVBQUm5aMGtyd1ZVOW0tVHBwZjJvNExIVXR6LU44ZEhoNWxxSlNEUWFpR1l5RGdTSVJhZTRMQ0tFZmxyZ0VhM0Z0ejl6Tjc3cnVfR1RGRlhPOW5SdVY4b3c?oc=5","date":"2025-05-22","type":"regulatory","source":"PR Newswire","summary":"Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign Strategic MOU to Advance T Regulatory Cell Therapies for Unmet Diseases - PR Newswire","headline":"Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign Strategic MOU to Advance T Regulatory Cell Th","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPdlBJdko1RFNSV2VycXJEdjhvV3JBMFZWcHQyTHU0blN6SzZqWE5WUFFfLXZndHVVQ1JqNGp2cTdFSnNmdmNkUHB0clF6Y3BMVFgwRVhRb1RBcUc5Tk4tZ1FLMjJUY1M1V0VuZy12RmpCMmtUenUtTG45THgxZFdaYy0wOExIejZJSTdxeU1YR0xZSTc5Q2REUjNKYzhleWZ5LVphV3JEMzhvaXFxSlFWcmhJSHFNaEFjNlE4Z1JuaEFabUhXT094cnoyOWhTWnJYSng0ekpWZlV6c2EtT2ZmbzFNSnpiQQ?oc=5","date":"2025-04-22","type":"pipeline","source":"PR Newswire","summary":"Cellenkos' Off-the-Shelf Treg Cell Therapy Shows Clinical Safety and Preliminary Efficacy in ALS - PR Newswire","headline":"Cellenkos' Off-the-Shelf Treg Cell Therapy Shows Clinical Safety and Preliminary Efficacy in ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAJBVV95cUxNZVZYLUdZRXVqTm1NVndkMS1Eb09hM19iTkNudWszUlR2M0JhWXFJaHhpTl9ZMlp2Z2h0bUlmWTdfLXUwOTNSbWdJYndLdUpnRkJSeVBlU3Y1c1FVS253eUZCTGVQMjM3NTNZUldQV05IcG1iMVFHMmtJalM4aXlzd0g2b3JNTmhkaXJvcUxlc1owT053ZlpScmV0aWFfTjVmSjZKQjdjdl9tOUlubXFPMEhQWHdqY2cwTFVOcnAzSXItS2t3NEEydUI4SWRnZVUxb1Q2R0xMUmJtMENSeV9iX3B2V3ZadXlYVXBpN2hDTk1mV2ZJdXVpVGFWQjFzamFLQXRTM1lHai1qMm5rSGtYckp6M0UydlpMOHo4ODRGZlFYQXdMYl9pTXFTSVFMSFF4NVlydzV1bVM?oc=5","date":"2025-04-14","type":"regulatory","source":"PR Newswire","summary":"Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Product) for Treatment of Aplastic Anemia - PR Newswire","headline":"Cellenkos Announces US FDA Orphan Drug Designation Granted to CK0801 (Allogeneic Cord Blood derived T regulatory Cell Pr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNbHhkcGpCSXFlSGxJaWxZQnN0bmcwdmpkUUhlSDJkamZNT3I0SHRfVG5oRy13R1diQV82T3dpV3FnV05XU3lSYkRKdXNGamE2d3REclBFaHlqd2RibTIzOXlRNGtSV1dtaVpWNjRZZWhIYzF6RDRVZnYySFhIamtMLUVEQzVib2VnOWRrajRrMVBHRWszZmJSWE41TDJhT1lla3c?oc=5","date":"2024-12-10","type":"trial","source":"PharmaTimes","summary":"Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis - PharmaTimes","headline":"Cellenkos presents promising phase 1b data for CK0804 in myelofibrosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPSG1oTU5xOVZVQm45QTIyMFBCdFpTZ0cyenk3SDZFUVBabDFoVVVCcWhadlpzVzZDRjRvWDhwLUpoLWRKRmtjU0JuMmx4MjMzTnVCZjRBN3ZYYUNxTFVwZXJWdWF3X1FpVEkyV1c5WGQ1S0NnUFVnRUs3RmFSV2VhSGJoX2VaSVRJQVhVVjhudEVsSGtOZFpmVEp3WjRzTl9CdGxmS1FCdXdIazZJRi1FbEY2c18xUmh3VUNXRUhlSUdIeHJ6amc3RmVzVXZPWlIyV0Z5ZzFVdHNBODhXenRNdWR1enI3Y1ZuY0RobFlaOEpiSkhpSm1uTXJ2eWZNNjgyeWc?oc=5","date":"2024-02-19","type":"regulatory","source":"PR Newswire","summary":"Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial - PR Newswire","headline":"Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOVHN1c01fY2EycVhhOGdnRjRCNl90LTgxY0lIOWlBVFdoSGRhZ3A5aDVZYUFIdk1Lb2hxMDNLRDBXQkJrdWVhalQ4amlxNWhvRmFmQld3V0pYbVVHSWFjQkg5QXl0c0V2cGNoajVwMEZUYmhrRnZ2Z3RPT2hrQ3FhYXBDNmUwNmFxNXlPYTJoandCbjVCcGlGbWhRQWp2dkVYUVRGbW8zUDJyanZkbjdXWjV6UkJLb2lad1dJbnVXdUE5MjNSTFlHa1Ffak9NQQ?oc=5","date":"2017-12-01","type":"pipeline","source":"PR Newswire","summary":"Cellenkos Inc. Appoints Tara Sadeghi as Senior Director of Clinical Operations - PR Newswire","headline":"Cellenkos Inc. Appoints Tara Sadeghi as Senior Director of Clinical Operations","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}